Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 6, 2016, Pages 1600-1605

  Ho, Peggy P ^a   Steinman, Lawrence ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bile acid agonist; Experimental autoimmune encephalomyelitis; Farnesoid X receptor; Multiple sclerosis; Obeticholic acid

Indexed keywords

CD19 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHENODEOXYCHOLIC ACID; FARNESOID X RECEPTOR; OBETICHOLIC ACID; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; VERY LATE ACTIVATION ANTIGEN 4; BILE ACID; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; LIGAND;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CHEMISTRY; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; IMMUNOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; KNOCKOUT MOUSE; METABOLISM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; BILE ACIDS AND SALTS; CHENODEOXYCHOLIC ACID; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; INJECTIONS, INTRAPERITONEAL; LIGANDS; LYMPHOCYTE ACTIVATION; MICE, KNOCKOUT; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84957827786     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1524890113     Document Type: Article

References (57)

1. Chiang JY (1998) Regulation of bile acid synthesis. Front Biosci 3:d176-d193.
2. Lambert G, et al. (2003) The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J Biol Chem 278(4):2563-2570.
3. Makishima M, et al. (1999) Identification of a nuclear receptor for bile acids. Science 284(5418):1362-1365.
4. Wang H, Chen J, Hollister K, Sowers LC, Forman BM (1999) Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 3(5):543-553.
5. Bishop-Bailey D, Walsh DT, Warner TD (2004) Expression and activation of the farnesoid X receptor in the vasculature. Proc Natl Acad Sci USA 101(10):3668-3673.
6. Forman BM, et al. (1995) Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81(5):687-693.
7. Mencarelli A, et al. (2009) The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. J Immunol 183(10):6657-6666.
8. Inagaki T, et al. (2006) Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci USA 103(10):3920-3925.
9. Vavassori P, Mencarelli A, Renga B, Distrutti E, Fiorucci S (2009) The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol 183(10):6251-6261.
10. Gadaleta RM, et al. (2010) Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease. Biochim Biophys Acta 1801(7):683-692.
11. Li YT, Swales KE, Thomas GJ, Warner TD, Bishop-Bailey D (2007) Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler Thromb Vasc Biol 27(12):2606-2611.
12. Hageman J, Herrema H, Groen AK, Kuipers F (2010) A role of the bile salt receptor FXR in atherosclerosis. Arterioscler Thromb Vasc Biol 30(8):1519-1528.
13. Schote AB, Turner JD, Schiltz J, Muller CP (2007) Nuclear receptors in human immune cells: Expression and correlations. Mol Immunol 44(6):1436-1445.
14. Pellicciari R, et al. (2004) Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid. J Med Chem 47(18):4559-4569.
15. Rizzo G, et al. (2010) Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. Mol Pharmacol 78(4): 617-630.
16. Zhang Y, et al. (2006) Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA 103(4):1006-1011.
17. Pellicciari R, et al. (2002) 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 45(17): 3569-3572.
18. Mudaliar S, et al. (2013) Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145(3):574-582.e1.
19. Ali AH, Carey EJ, Lindor KD (2015) Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med 3(1):5.
20. Neuschwander-Tetri BA, et al.; NASH Clinical Research Network (2015) Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial. Lancet 385(9972): 956-965.
21. Trivedi PJ, Hirschfield GM, Gershwin ME (2016) Obeticholic acid for the treatment of primary biliary cirrhosis. Expert Rev Clin Pharmacol 9(1):13-26.
22. Zamvil SS, Steinman L (1990) The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol 8:579-621.
23. Lassmann H, Brunner C, Bradl M, Linington C (1988) Experimental allergic encephalomyelitis: The balance between encephalitogenic T lymphocytes and demyelinating antibodies determines size and structure of demyelinated lesions. Acta Neuropathol 75(6):566-576.
24. Linington C, Bradl M, Lassmann H, Brunner C, Vass K (1988) Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 130(3):443-454.
25. McCormack PL (2013) Natalizumab: A review of its use in the management of relapsing- remitting multiple sclerosis. Drugs 73(13):1463-1481.
26. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ (2007) The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 8(3): 239-245.
27. Nurieva RI, Liu X, Dong C (2009) Yin-Yang of costimulation: Crucial controls of immune tolerance and function. Immunol Rev 229(1):88-100.
28. Francisco LM, Sage PT, Sharpe AH (2010) The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236:219-242.
29. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL (2004) SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 173(2):945-954.
30. Ishida Y, Agata Y, Shibahara K, Honjo T (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11(11):3887-3895.
31. Riley JL (2009) PD-1 signaling in primary T cells. Immunol Rev 229(1):114-125.
32. Watanabe N, et al. (2003) BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 4(7):670-679.
33. Le Mercier I, Lines JL, Noelle RJ (2015) Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators. Front Immunol 6:418.
34. SospedraM, Martin R (2005) Immunology of multiple sclerosis. Annu Rev Immunol 23: 683-747.
35. Babbe H, et al. (2000) Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 192(3):393-404.
36. Skulina C, et al. (2004) Multiple sclerosis: Brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc Natl Acad Sci USA 101(8): 2428-2433.
37. Hauser SL, et al. (1986) Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann Neurol 19(6):578-587.
38. Huseby ES, et al. (2001) A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J Exp Med 194(5):669-676.
39. Sun D, et al. (2001) Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J Immunol 166(12):7579-7587.
40. York NR, et al. (2010) Immune regulatory CNS-reactive CD8+T cells in experimental autoimmune encephalomyelitis. J Autoimmun 35(1):33-44.
41. Ortega SB, Kashi VP, Cunnusamy K, Franco J, Karandikar NJ (2015) Autoregulatory CD8 T cells depend on cognate antigen recognition and CD4/CD8 myelin determinants. Neurol Neuroimmunol Neuroinflamm 2(6):e170.
42. Brinkmann V, et al. (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277(24):21453-21457.
43. McGillicuddy FC, et al. (2009) Inflammation impairs reverse cholesterol transport in vivo. Circulation 119(8):1135-1145.
44. Myant NB, Mitropoulos KA (1977) Cholesterol 7 alpha-hydroxylase. J Lipid Res 18(2): 135-153.
45. Dunn SE, et al. (2006) Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med 203(2):401-412.
46. Youssef S, et al. (2002) The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420(6911):78-84.
47. Stüve O, et al. (2006) Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest 116(4):1037-1044.
48. Stanislaus R, Pahan K, Singh AK, Singh I (1999) Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci Lett 269(2):71-74.
49. Daynes RA, Jones DC (2002) Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2(10):748-759.
50. Barbier O, et al. (2002) Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 22(5): 717-726.
51. Dunn SE, et al. (2010) Peroxisome proliferator-activated receptor delta limits the expansion of pathogenic Th cells during central nervous system autoimmunity. J Exp Med 207(8):1599-1608.
52. Dunn SE, et al. (2007) Peroxisome proliferator-activated receptor (PPAR)alpha expression in T cells mediates gender differences in development of T cell-mediated autoimmunity. J Exp Med 204(2):321-330.
53. Lovett-Racke AE, et al. (2004) Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J Immunol 172(9):5790-5798.
54. Polak PE, et al. (2005) Protective effects of a peroxisome proliferator-activated receptor-beta/delta agonist in experimental autoimmune encephalomyelitis. J Neuroimmunol 168(1-2):65-75.
55. Klotz L, et al. (2009) The nuclear receptor PPAR gamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity. J Exp Med 206(10):2079-2089.
56. Diab A, et al. (2002) Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12, 14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J Immunol 168(5):2508-2515.
57. Feinstein DL, et al. (2002) Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol 51(6):694-702.